A coalition of attorneys general from 38 U. S. states is urging the FDA to take action against counterfeit versions of weight loss and diabetes medications, such as Ozempic and Mounjaro. These fake drugs pose serious health risks to consumers.
• Call for FDA Action: Attorneys general are pushing the FDA to protect the public from counterfeit GLP-1 medications. This includes using enforcement tools against those selling fake drugs.
• Counterfeit Drug Risks: The letter highlights that counterfeit drugs can contain harmful substances or unknown drugs, leading to serious side effects, including hospitalization. Many consumers cannot identify fake from legitimate products.
• Sources of Counterfeits: The fake medications often come from countries like China, Turkey, and India. Scammers have even sold repackaged insulin as Ozempic.
• Illegal Online Sales: Some retailers are selling active ingredients of GLP-1 drugs without prescriptions, increasing risks of contamination. Consumers mixing their own medications may lack the knowledge for safe handling.
• Compounding Pharmacies Issues: Certain compounding pharmacies have been discovered to produce unsafe versions of GLP-1 medications, leading to concerns about safety and efficacy.
• Public Health Incidents: Reports of health issues linked to fake Ozempic have emerged, including cases of hospitalization due to seizures and hypoglycemia.
• FDA Responses: The FDA has seized counterfeit drugs and assured the public that legitimate GLP-1 medications are now back in supply, though some localized shortages may still occur.
The attorneys general's letter demands that the FDA enhance its efforts to combat counterfeit GLP-1 drugs by working with other federal agencies and ensuring that compounding pharmacies adhere to safety regulations. The issues surrounding these counterfeit medications highlight the significant risks posed to consumers seeking effective weight loss treatments.
Comments
Post a Comment